Genetically engineered tumor cell vaccine in a head and neck cancer model

Laryngoscope

Volumn 113, Issue 3, 2003, Pages 552-556

  Couch, Marion ^a   Saunders, John K ^a   O'Malley Jr , Bert W ^b   Pardoll, Drew ^a   Jaffee, Elizabeth ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; GM CSF; Tumor vaccine

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSARCOMA; GENE EXPRESSION; GENETIC ENGINEERING; HEAD AND NECK CANCER; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATION; IRRADIATION; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VACCINATION;

ANIMALS; CANCER VACCINES; CARCINOMA, SQUAMOUS CELL; FEMALE; GENETIC ENGINEERING; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; MICE; MICE, INBRED C3H; RETROVIRIDAE; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037336366     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-200303000-00029     Document Type: Article

References (20)

1. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-1060.
2. Simons JW, Mikhak B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin Oncol 1998;25:661-676.
3. Simons JW, MiKhak B, Chang J, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Can Research 1999;59:5160-5168.
4. Wakimoto H, Abe J, Tsunoda R, et al. Intensified antitumor immunity by a cancer vaccine that produces granulocytemacrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996;56:1828-1833.
5. Jaffee EM, Lazenby A, Meurer J, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunotherapy 1995;18:1-9.
6. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-3543.
7. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-1702.
8. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368.
9. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
10. O'Malley BW, Cope KA, Johnson CS. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-24.
11. Myers JN, Mank-Seymour A, Zitvogel L, et al. Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice. Laryngoscope 1998;108:261-268.
12. Nanni P, Rossi I, De Giovanni C, et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastasis. Cancer Res 1998;58:1225-1230.
13. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;0:397-403.
14. Nagashima S, Reichert TE, Kashii Y. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2. Cancer Gene Ther 1997;4:366-376.
15. Tuting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. J Mol Med 1997;75:478-491.
16. Jaffee EM, Dranoff G, Cohen LK, et al. High efficiency gene transfer into primary human tumor explants without selection. Cancer Res 1993;53:2221-2226.
17. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci 1998;95:13141-13146.
18. Thomas MC, Greten TF, Pardoll DM, et al. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998;9:835-843.
19. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.
20. Chang AE, Redman BC, Whitfield JR. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clinical Cancer Res 2002;8:1021-1032.